Sanofi India Limited receives ₹12.37 Crore tax order for FY23
Sanofi India Limited received a final tax assessment order for FY 2022-23 from the Income Tax Department. The order includes a tax liability of ₹12.37 crore, including interest, due to transfer pricing adjustments and disallowances. The company plans to appeal the order.
The tax order represents a substantial financial liability for the company, though the company plans to appeal, which could mitigate the impact.
The company has received a tax order with a significant financial liability, which is a negative development.
Sanofi India Limited has received a final assessment order for the Financial Year 2022-23 (Assessment Year 2023-24) from the Assessment Unit of the Income Tax Department. The order determines a total tax liability of ₹12,36,99,710 (approximately ₹12.37 crore), including interest.
This tax liability arises from adjustments made concerning transfer pricing issues and the disallowance of payments made to healthcare professionals. The company received this order on 27th March 2026.
Sanofi India Limited intends to appeal the adjustments and disallowances made in this assessment order before the Higher Tax Authorities. The company has stated that this is for information and records.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.